ADC Therapeutics SA

ADCT NYSE SEC CIK 1771910
Follow ADC Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2022 USD · IFRS
Revenue, last year $209.9M +518.9% vs prior year
Net income −$155.8M +32.3% vs prior year
EPS, diluted -
Operating cash flow −$136.8M +41.4% vs prior year
Revenue by fiscal year
$1.1M
$2.3M
$0
$33.9M
$209.9M
FY18 FY19 FY20 FY21 FY22

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY17FY18FY19FY20FY21FY22
Show the numbers
YearRevenueNet income
FY22$209.9M−$155.8M
FY21$33.9M−$230M
FY20$0−$246.3M
FY19$2.3M−$116.5M
FY18$1.1M−$123.1M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%5000%FY17FY18FY19FY20FY21FY22
Show the numbers
YearGross marginOperating marginNet margin
FY2297.8%−58.9%−74.2%
FY2195.9%−771.6%−678.2%
FY20---
FY19100%−5102.5%−4977.9%
FY18-−11047.5%−10797.9%
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY17FY18FY19FY20FY21FY22
Show the numbers
YearFree cash flow
FY22−$137.4M
FY21−$236.8M
FY20−$169.5M
FY19−$121.9M
FY18−$122.3M
FY17-
Returned to shareholdersDividends paid and shares bought back
$0$50K$100K$150KFY17FY18FY19FY20FY21FY22
Show the numbers
YearBuybacks
FY22-
FY21$0
FY20$0
FY19$141K
FY18$0
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • ADC Therapeutics
  • Healthcare median
−15000%−10000%−5000%0%FY17FY18FY19FY20FY21FY22
Show the numbers
YearADC TherapeuticsHealthcare median
FY22−74.2%−80.4%
FY21−678.2%−71.9%
FY20-−62.2%
FY19−4977.9%−46.3%
FY18−10797.9%−49.6%
FY17-−45.9%